Washington, May 3 (Prensa Latina) Following a 60-year scientific quest, the world has its first vaccine to protect from respiratory syncytial virus (or RSV) and more are on the way. On Wednesday, the US Food and Drug Administration (FDA) approved the new GSK-made Arexvy vaccine, which is designed to be given as a single shot to adults 60 and older.